Trial Profile
A Randomised, Open-labelled, Active-controlled, Multiple Dose, Dose Escalating, Sequential Dose Group Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-weekly Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Compared to Once-daily Norditropin NordiFlex in Adults With Growth Hormone Deficiency
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 17 Apr 2021 Pooled modelling analysis of data from ClinicalTrials.gov identifiers NCT01973244, NCT00936403 and NCT01706783 published in the Clinical Pharmacokinetics
- 12 Dec 2020 Results of a pooled analysis (NCT01514500, NCT01706783 and ) data from assessing the pharmacokinetic/pharmacodynamics model published in the Journal of Clinical Endocrinology and Metabolism
- 18 Apr 2018 Results assessing pooled pharmacokinetic/pharmacodynamic modeling analysis of data from three phase I studies published in the Clinical Pharmacokinetics.